U.S. Building Stock News

Gaming and Leisure Properties (GLPI) opened 2026 with Q1 revenue of US$420 million and basic EPS of US$0.82, while trailing twelve month EPS reached US$3.17 and net income came in at US$891 million with a 55% net margin. Over the past year, revenue has moved from US$1.55 billion to US$1.62 billion and trailing basic EPS has gone from US$2.83 to US$3.17, alongside earnings growth of 15% and an increase in net margin from 50% to 55%. Together with trailing funds from operations of about US$1.11...

Cabot stock performance snapshot Cabot (CBT) has drawn investor attention after posting annual revenue of US$3.6b and net income of US$306.0m, alongside mixed total return figures that range from a slight 1 year decline to multi year gains. See our latest analysis for Cabot. The share price has gathered some positive momentum recently, with a 7 day share price return of 3.25% and a year to date share price return of 14.62%. This comes even though the 1 year total shareholder return is...

Dickies and Harley-Davidson announced in April 2026 that they reunited for a second limited-edition “Built to Outlast” apparel collection, now available on both brands’ online stores and select Harley-Davidson dealerships. The renewed capsule extends Harley-Davidson’s reach beyond motorcycles into lifestyle workwear, reinforcing the brand’s cultural relevance with younger and apparel-focused consumers. Next, we’ll examine how this renewed Dickies collaboration, and its focus on lifestyle...

TE Connectivity (TEL) is back in focus after reporting fiscal Q2 results tied to record orders, raised guidance and higher capital spending, alongside a larger dividend and a growing AI focused backlog. See our latest analysis for TE Connectivity. Despite strong Q2 figures and higher guidance, TE Connectivity's share price has been volatile, with a 12.8% 7 day share price decline and a 7.9% year to date share price decline, set against a 50.8% 1 year total shareholder return. This suggests...

Packaging Corporation of America (NYSE:PKG) reported strong first quarter operational performance, with record corrugated shipments in its legacy operations despite cost and weather headwinds. The company highlighted progress integrating Greif’s containerboard business, including efficiency gains across the Packaging segment. PCA outlined substantial annual synergy targets from the Greif integration and is implementing significant price increases in its packaging business. Packaging...

Rapport Therapeutics recently reported Phase 2a follow-up data for its investigational epilepsy drug RAP-219 in drug-resistant focal onset seizures, showing sustained reductions in both long episodes and clinical seizures over a 16-week period with generally favorable tolerability. An intriguing aspect of the update is RAP-219’s longer-than-previously-estimated 22-day half-life, which appears to maintain therapeutic receptor occupancy and seizure control well beyond the initial 8-week dosing...

Executive change in APAC puts regional growth focus in the spotlight nCino (NCNO) has appointed Nick Edwards as Managing Director for Asia Pacific, a move that points to a sharper regional focus and gives investors a fresh angle to reassess the stock’s growth ambitions. See our latest analysis for nCino. The latest executive appointment comes against a mixed backdrop, with a 22.10% 1 month share price return alongside a 27.24% 3 month share price decline and a 23.26% 1 year total shareholder...

Earlier this week, TJ Biopharma announced a definitive agreement under which Biogen will acquire its exclusive Greater China rights to felzartamab for up to US$850 million, giving Biogen worldwide control of the Phase 3 anti-CD38 antibody and responsibility for future development, manufacturing, and commercialization in the region. This deal consolidates felzartamab under one owner across multiple immune-mediated diseases and multiple myeloma in China, tightening the link between Biogen’s...

Richmond Mutual Bancorporation (RMBI) opened 2026 with Q1 results framed by trailing 12 month revenue of about US$46.8 million, basic EPS of US$1.20 and earnings growth of 23.5% versus the prior year. Over recent quarters, revenue has ranged from about US$10.7 million to US$12.6 million per quarter while basic EPS moved between roughly US$0.20 and US$0.37. This sets up a picture of steady top line performance and a higher earnings base that now feeds into a net profit margin of 24.8%. For...

SiriusPoint recently received an upgrade from S&P Global Ratings, which raised the financial strength ratings of its core insurance subsidiaries to ‘A’ and the holding company rating to ‘BBB+,’ citing a stronger capital position, consistent underwriting results, and a lower-risk underwriting and investment profile. This higher credit profile could broaden SiriusPoint’s access to capital and counterparties, potentially reinforcing confidence in its underwriting platform and balance sheet...

Why Group 1 Automotive Is On Investors’ Radar Today Group 1 Automotive (GPI) has attracted fresh attention after recent trading left the stock with mixed return patterns, including a loss over the past 3 months but a gain over the past month. See our latest analysis for Group 1 Automotive. The recent 1 month share price return of 4.45% contrasts with a 3 month share price decline of 12.89% and a 1 year total shareholder return loss of 15.60%. This suggests that momentum has started to...

Avatier launched an auto enrolled, air gapped Multi Factor Authentication solution called the Identity Challenge Card after a recent cyberattack disrupted Stryker's identity systems. The card operates without smartphones, apps, or internet connectivity, aiming to keep authentication running when traditional identity tools are offline. The development is being watched as part of broader efforts to support operational resilience and business continuity in healthcare. Stryker (NYSE:SYK) enters...

Intellia Therapeutics (NasdaqGM:NTLA) plans to announce topline results from the first Phase 3 trial of an in vivo CRISPR gene editing candidate for hereditary angioedema. The upcoming readout will be the first-ever Phase 3 data release for an in vivo CRISPR therapy. The results are expected to be highly relevant for Intellia's future plans and for gene editing drug development more broadly. Intellia Therapeutics, trading at around $13.63, sits at the center of attention as it approaches a...

Earlier this week, ServiceNow reported first-quarter 2026 results with revenue of US$3.77 billion and modestly higher earnings, while also updating guidance and detailing margin headwinds linked to its Armis acquisition. A key development was ServiceNow’s deepened AI alliance with Google Cloud and new autonomous workflow wins such as TridentCare, underscoring how AI agents and unified data governance are increasingly embedded across its platform and customer base. We’ll now examine how...

In April 2026, F.N.B. Corporation reported first-quarter results showing year-over-year growth in net interest income to US$359.28 million and net income to US$137.05 million, modestly higher net charge-offs of US$15.9 million, largely unchanged full-year 2026 net interest income guidance of US$1.495–1.535 billion, and second-quarter guidance of US$370–380 million. Alongside these results, the board raised the quarterly dividend to US$0.13 per share and backed a new US$250 million buyback...

In the first quarter of 2026, GE Aerospace reported revenue of US$12,392 million versus US$9,935 million a year earlier, with net income easing to US$1,904 million while basic EPS from continuing operations edged up to US$1.85. Alongside this, GE Aerospace continued sizeable share repurchases under its 2024 authorization and faced a US$36 million ITAR-related civil penalty, highlighting both active capital returns and ongoing compliance remediation. We’ll now examine how strong revenue...

Cintas Corporation previously announced that its Board of Directors approved a quarterly cash dividend of US$0.45 per share, payable on June 15, 2026, to shareholders of record as of May 15, 2026, extending a 42-year streak of annual dividend increases since its 1983 IPO. This latest dividend decision, alongside a history of consistently raising payouts, highlights Cintas’ ongoing emphasis on returning capital to shareholders as a core element of its business model. Next, we’ll examine how...

In the past week, e.l.f. Beauty prepared for its upcoming earnings release, with analysts expecting earnings of US$0.30 per share and revenue growth of more than 28% year over year, pointing to rising sales but pressure on profitability. This combination of expanding top line and weaker earnings per share highlights how rising costs, investment, or mix shifts may be affecting the company’s ability to convert sales into profit. We’ll now examine how the anticipated revenue growth alongside a...

Everforth’s recent share slide Everforth (ASGN) has seen its share price under pressure, with the stock down about 52% over the past month and 63% over the past 3 months, drawing attention to its current valuation. See our latest analysis for Everforth. The recent 52% 7 day share price decline and 59% year to date share price return continue a longer trend, with a 63% 1 year total shareholder return loss pointing to fading momentum as investors reassess Everforth’s risk and growth profile. If...

Investors may be wondering whether Kimberly-Clark at around US$97.85 is starting to look attractively priced, or if the recent share price reflects too much confidence in its future. The stock has delivered returns of a 1% decline over 7 days, a 1.5% decline over 30 days and a 3.5% decline year to date, adding to a 22.3% decline over the last year and a 24.1% decline over three years. These moves have come alongside ongoing investor focus on consumer staples companies and how they are...

If you are wondering whether Ladder Capital is a bargain at around US$10.34, the key question is not just where the share price is today, but what that price actually implies about the business. The stock has moved only slightly over the past week with a 0.4% decline, yet it has returned 10.3% over the last year and 42.3% over three years. This provides useful context before comparing that performance to what the current valuation suggests. No major company specific headlines have recently...

Wondering if Sysco at around US$76.56 is still a fair deal or starting to look expensive? This article breaks down what the current share price might be implying about the company. Over shorter periods, the stock has been mixed, with a 0.4% return over 7 days, a 7.5% decline over 30 days, a 5.4% gain year to date, and 11.0% over the last year, which can change how investors think about both opportunity and risk. Recent coverage has focused on Sysco's role in the food distribution sector,...

In recent days, Eli Lilly’s newly approved oral GLP-1 weight-loss drug Foundayo has shown slower-than-hoped prescription uptake, lagging Novo Nordisk’s oral Wegovy and raising questions about Lilly’s competitive position in the expanding obesity market. At the same time, Lilly is reshaping its pipeline through moves such as exiting a RIPK1 collaboration with Rigel and agreeing to acquire Kelonia Therapeutics for about US$3.25 billion upfront to deepen its oncology and genetic medicines...

D.R. Horton, Inc. recently reported fiscal second-quarter 2026 results, with sales of US$7,365.3 million and net income of US$647.9 million, alongside updated full-year revenue guidance of US$33.5 billion to US$34.5 billion, a US$0.45 per share dividend declaration, and completion of a US$3.29 billion share repurchase program covering 7.77% of shares. While revenue and earnings were lower than a year earlier, management pointed to double-digit growth in net sales orders, reduced unsold...